EGFR and non-small cell lung carcinoma: The clinical outcome data from this cohort of the CHRYSALIS trial led to an FDA approval of amivantamab for the treatment of adult patients with locally advanced NSCLC with the EGFR exon 20 insertion mutation, whose disease has progressed on or after platinum-based chemotherapy [20].